The Medicines and Healthcare products Regulatory Agency has given market authorisation to Ipsen and Gladerma’s new wrinkle therapy Azzalure, which works by relaxing the muscles around the eyes.

Specifically, the Agency has approved the ‘botox’ Azzalure (botulinum toxin Type A) for the temporary improvement of moderate-to-severe glabellar lines - which appear as vertical lines between the eyebrows - in patients aged 65 years and under who are affected psychologically by them.

The green light was based on a comprehensive clinical trial programme with more than 2,600 patients, which showed the agent offers a safe, effective and easy to use option for the temporary improvement of glabellar lines, according to the companies.

The groups are certainly excited about Azzalure’s potential, given the fast growth in the UK corrective and aesthetic marketplace, which, they say, is valued at over £20 million in drug terms alone.

A market launch is scheduled for the second quarter of this year.